Coronary disease & ACS

Comprehensive Non-invasive Versus Invasive Approach to Evaluate Cardiac Allograft Vasculopathy in Heart Transplantation: The CCTA-HTx Study

Circ Cardiovasc ImagingPublished multicenter prospective study

Authors' conclusion

A noninvasive strategy based on CCTA is accurate for managing patients with HTx. CCTA might be considered the preferred imaging modality for annual CAV surveillance after the first year post-HTx.

Study context

Population
Patients with heart transplant (HTx) who underwent coronary computed tomography angiography (CCTA), invasive coronary angiography, intravascular ultrasound, and fractional flow reservepatients with HTx
Participants
37 patients
Exposure
Comprehensive CCTA-based approach compared with the invasive reference, which includes invasive coronary angiography, intravascular ultrasound, and fractional flow reserve, for detecting cardiac allograft vasculopathy (CAV)
Outcome
CAV diagnosis
Follow-up
Median interval between CCTA and HTx 5 years

Main finding

As reported in the abstract

Diagnosed with CAV

23

62.2%

Observational data: associations, not effects.

Further findings

Diagnostic performance of integration of diameter stenosis and plaque morphology (plaque burden at minimum lumen area >42% and percent atheroma volume >23%) at CCTA

Accuracy
84%
Sensitivity
83%
Specificity
86%
  • Highest diagnostic performance

Integration of ∆fractional flow reserve derived from coronary computed tomography trans-vessel gradient

Increased sensitivity, albeit with decreased specificity and overall accuracy

Safety

Lower contrast and radiation dose with the noninvasive approach, compared with the invasive approach

Original publication

Comprehensive Non-invasive Versus Invasive Approach to Evaluate Cardiac Allograft Vasculopathy in Heart Transplantation: The CCTA-HTx Study. Circ Cardiovasc Imaging. Published 7 January 2025. doi:10.1161/circimaging.124.017197

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.